PDF(Pubmed)
Abstract：
CONCLUSIONS: In reducing intraocular pressure (IOP), Paul (PGI) and Baerveldt (BGI) glaucoma implants are safe and effective in patients with glaucoma.
OBJECTIVE: To compare efficacy and safety profiles of the PGI and BGI in the treatment of medically uncontrolled glaucoma at 1 year of follow-up.
METHODS: Retrospective analysis of patients implanted with a PGI or BGI with a minimum of 12 months follow-up. The primary outcome was surgical success defined as IOP ≥6 and ≤18 mm Hg and at least 20% IOP reduction from baseline. Secondary outcomes included IOP measurements, number of medications, and complications.
RESULTS: Twenty-three patients implanted with PGI and 27 with BGI were included. At last visit (12 mo), mean IOP had decreased from 23.7 ± 6.9 to 0.1 ± 2.9 mm Hg in the PGI group versus 26 ± 7.3 to 10.4 ± 4.9 mm Hg with the BGI ( P < 0.001 for both comparisons). Overall qualified success rates were similar between groups (PGI 91% vs BGI 89%, P = 0.784). IOP was significantly lower in the PGI at week 1 and month 1 of follow-up versus the BGI (13.6 ± 6.1 vs 20.1 ± 7.4; 14.6±3.8 vs 21.2 ± 5.8 mm Hg; P < 0.002 for both) with a lower number of medications (1.57 ± 1.47 vs 2.52 ± 1.16 at mo 1, P = 0.015). Most complications were minor and similar in both groups.
CONCLUSIONS: Both PGI and BGI are safe and effective in reducing IOP in patients with glaucoma, with similar success rates.
OBJECTIVE: To compare efficacy and safety profiles of the PGI and BGI in the treatment of medically uncontrolled glaucoma at 1 year of follow-up.
METHODS: Retrospective analysis of patients implanted with a PGI or BGI with a minimum of 12 months follow-up. The primary outcome was surgical success defined as IOP ≥6 and ≤18 mm Hg and at least 20% IOP reduction from baseline. Secondary outcomes included IOP measurements, number of medications, and complications.
RESULTS: Twenty-three patients implanted with PGI and 27 with BGI were included. At last visit (12 mo), mean IOP had decreased from 23.7 ± 6.9 to 0.1 ± 2.9 mm Hg in the PGI group versus 26 ± 7.3 to 10.4 ± 4.9 mm Hg with the BGI ( P < 0.001 for both comparisons). Overall qualified success rates were similar between groups (PGI 91% vs BGI 89%, P = 0.784). IOP was significantly lower in the PGI at week 1 and month 1 of follow-up versus the BGI (13.6 ± 6.1 vs 20.1 ± 7.4; 14.6±3.8 vs 21.2 ± 5.8 mm Hg; P < 0.002 for both) with a lower number of medications (1.57 ± 1.47 vs 2.52 ± 1.16 at mo 1, P = 0.015). Most complications were minor and similar in both groups.
CONCLUSIONS: Both PGI and BGI are safe and effective in reducing IOP in patients with glaucoma, with similar success rates.
摘要：
结论：在降低眼内压（IOP）方面，Paul（PGI）和Baerveldt（BGI）青光眼植入物对青光眼患者安全有效。
目的：比较PGI和BGI在1年随访时治疗药物未控制的青光眼的疗效和安全性。
方法：对植入PGI或BGI的患者进行回顾性分析，至少随访12个月。主要结果是手术成功，定义为IOP≥6和≤18mmHg，并且IOP比基线降低至少20％。次要结果包括眼压测量，药物的数量,和并发症。
结果：纳入23例PGI植入患者和27例BGI植入患者。在最后一次访问（12个月），PGI组的平均IOP从23.7±6.9降至0.1±2.9mmHg,而BGI组的平均IOP从26±7.3降至10.4±4.9mmHg(两个比较P<0.001).总体合格成功率在组间相似(PGI91%vsBGI89%，P=0.784）。与BGI相比，PGI在随访的第1周和第1个月的IOP显着降低（13.6±6.1vs20.1±7.4；14.6±3.8vs21.2±5.8mmHg；两者P<0.002），药物数量较低（1月1.57±1.47vs2.52±1.16，P=0.015）。两组的大多数并发症都是轻微的，相似。
结论：PGI和BGI在降低青光眼患者眼压方面均安全有效，成功率相似。
目的：比较PGI和BGI在1年随访时治疗药物未控制的青光眼的疗效和安全性。
方法：对植入PGI或BGI的患者进行回顾性分析，至少随访12个月。主要结果是手术成功，定义为IOP≥6和≤18mmHg，并且IOP比基线降低至少20％。次要结果包括眼压测量，药物的数量,和并发症。
结果：纳入23例PGI植入患者和27例BGI植入患者。在最后一次访问（12个月），PGI组的平均IOP从23.7±6.9降至0.1±2.9mmHg,而BGI组的平均IOP从26±7.3降至10.4±4.9mmHg(两个比较P<0.001).总体合格成功率在组间相似(PGI91%vsBGI89%，P=0.784）。与BGI相比，PGI在随访的第1周和第1个月的IOP显着降低（13.6±6.1vs20.1±7.4；14.6±3.8vs21.2±5.8mmHg；两者P<0.002），药物数量较低（1月1.57±1.47vs2.52±1.16，P=0.015）。两组的大多数并发症都是轻微的，相似。
结论：PGI和BGI在降低青光眼患者眼压方面均安全有效，成功率相似。
